The study focuses on Bifidobacterium breve BBr16, a probiotic strain capable of alleviating age-related cognitive impairments.

This invention relates to a composite probiotic for improving bacterial vaginosis (BV), a probiotic agent, and its application. The composite probiotic comprises Lacticaseibacillus paracasei LC86 and Lacticaseibacillus rhamnosus LRa66.

This study explores the properties and applications of Lactobacillus acidophilus LA18. Isolated and preserved under the code CCTCC NO: M 2022572, LA18 demonstrates significant potential in regulating gut microbiota, modulating immune responses, and producing short-chain fatty acids (SCFAs)

The invention pertains to a probiotic agent designed to modulate the gut hormone GLP-1 levels, encompassing the Lacticaseibacillus rhamnosus LRa05 strain (CGMCC No.1.12734) and its application in obesity treatment.

This study explores the potential of Lacticaseibacillus rhamnosus LRa05 as a novel probiotic treatment for Candidal vaginitis. Isolated from fecal samples, LRa05 demonstrates superior antagonistic activity against Candida albicans, surpassing commercially available strains LGG, RC-14, and GR-1.

Chronic kidney disease (CKD) is a significant health concern characterized by the accumulation of uremic toxins in the blood, which are difficult to remove via dialysis. This study presents a novel probiotic composition, comprising Lacticaseibacillus rhamnosus LRa66 and Bifidobacterium bifidum BBi32, designed to regulate serum uremic toxins and alleviate CKD symptoms.